InMed Pharmaceuticals Inc
INM1.230USD
-0.030-2.38%
收盤 12/24, 13:00（美東）報價延遲15分鐘
3.20M總市值
0.03本益比TTM
關於 InMed Pharmaceuticals Inc 公司
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Inc簡介
公司代碼INM
公司名稱InMed Pharmaceuticals Inc
上市日期Jun 21, 2001
CEOAdams (Eric A)
員工數量- -
證券類型Ordinary Share
年結日Jun 21
公司地址1445-885 West Georgia St.
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編V6C 3E8
電話16046697207
網址https://www.inmedpharma.com/
公司代碼INM
上市日期Jun 21, 2001
CEOAdams (Eric A)
InMed Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Sabby Management, LLC
7.85%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
其他
86.68%
持股股東
持股股東
佔比
Sabby Management, LLC
7.85%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
其他
86.68%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
10.71%
Investment Advisor
1.64%
Research Firm
0.74%
Hedge Fund
0.60%
Individual Investor
0.15%
其他
86.16%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
30
135.23K
4.82%
+48.77K
2025Q2
37
127.03K
6.34%
+18.71K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
2023Q2
37
1.04K
0.99%
-13.60K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Sabby Management, LLC
36.13K
1.52%
+20.77K
+135.22%
Dec 31, 2024
Yorkville Advisors Global, LP.
80.37K
3.37%
+80.37K
--
Dec 13, 2024
Adams (Eric Ashley)
2.20K
0.09%
-5.70K
-72.17%
Jun 30, 2025
Hull (Andrew Harold)
1.91K
0.08%
-425.00
-18.19%
Jun 30, 2025
SBI Securities Co., Ltd.
300.00
0.01%
--
--
Jun 30, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
公告日期
類型
比率
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
常見問題
InMed Pharmaceuticals Inc的前五大股東是誰？
InMed Pharmaceuticals Inc的前五大股東如下：
Sabby Management, LLC持有股份：36.13K佔總股份比例：1.52%。
Yorkville Advisors Global, LP.持有股份：80.37K佔總股份比例：3.37%。
Adams (Eric Ashley)持有股份：2.20K佔總股份比例：0.09%。
Hull (Andrew Harold)持有股份：1.91K佔總股份比例：0.08%。
SBI Securities Co., Ltd.持有股份：300.00佔總股份比例：0.01%。
Sabby Management, LLC持有股份：36.13K佔總股份比例：1.52%。
Yorkville Advisors Global, LP.持有股份：80.37K佔總股份比例：3.37%。
Adams (Eric Ashley)持有股份：2.20K佔總股份比例：0.09%。
Hull (Andrew Harold)持有股份：1.91K佔總股份比例：0.08%。
SBI Securities Co., Ltd.持有股份：300.00佔總股份比例：0.01%。
InMed Pharmaceuticals Inc的前三大股東類型是什麼？
InMed Pharmaceuticals Inc 的前三大股東類型分別是：
Sabby Management, LLC
Yorkville Advisors Global, LP.
DRW Securities, LLC
Sabby Management, LLC
Yorkville Advisors Global, LP.
DRW Securities, LLC
有多少機構持有InMed Pharmaceuticals Inc(INM)的股份？
截至2025Q3，共有30家機構持有InMed Pharmaceuticals Inc的股份，合計持有的股份價值約為135.23K，占公司總股份的4.82% 。與2025Q2相比，機構持股有所增加，增幅為-1.52%。
哪個業務部門對InMed Pharmaceuticals Inc的收入貢獻最大？
在--，--業務部門對InMed Pharmaceuticals Inc的收入貢獻最大，創收--，占總收入的--% 。
